Allergan   1Q Revenues: $1.6 billion (+13%) 1Q Earnings: $257.9 million (earnings were $14.4 million in 1Q13) Comments: Specialty pharmaceuticals sales increased 10% to $1.4 billion, with Eye Care Pharmaceutical sales of $730.4 million, up 9%, and Botox/Neuromodulators sales up 10% to $501.8 million. Medical devices sales increased 29% to $259.8 million. Earnings in 1Q13 include $258.6 million from discontinued operations associated with the sale of the obesity intervention business unit. On ...